Objective response rate assessment in oncology: Current situation and future expectations

doi:10.5306/wjco.v11.i2.53

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 2

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (25903)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-9) series.

Item

Count

PDF

2354

WORD

341

HTML

18358

Figures (1-4)

1481

Tables (1-9)

842

Sum=23376

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

819

Download

1711

Sum=2530

Feb 24, 2020 (publication date) through Feb 23, 2026

Times Cited of This Article

Times Cited (76)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Review

World J Clin Oncol. Feb 24, 2020; 11(2): 53-73
Published online Feb 24, 2020. doi: 10.5306/wjco.v11.i2.53

Objective response rate assessment in oncology: Current situation and future expectations

Nuri Faruk Aykan, Tahsin Özatlı

Nuri Faruk Aykan, Tahsin Özatlı, Department of Medical Oncology, Istinye University Medical School, Bahcesehir Liv Hospital, Istanbul 34510, Turkey

Author contributions: Aykan NF and Özatlı T performed the literature search; and Aykan NF wrote the manuscript.

Conflict-of-interest statement: No potential conflicts of interest and no financial support are associated with this manuscript.

Corresponding author: Nuri Faruk Aykan, MD, Professor, Department of Medical Oncology, Istinye University Medical School, Bahcesehir Liv Hospital, Atatürk Bulvarı, No. 6, Istanbul 34510, Turkey. nfaruk@mac.com

Received: May 5, 2019
Peer-review started: May 8, 2019
First decision: October 23, 2019
Revised: November 5, 2019
Accepted: November 28, 2019
Article in press: November 28, 2019
Published online: February 24, 2020
Processing time: 297 Days and 18.6 Hours

Core Tip

Core tips: The tumor objective response rate is an important parameter in oncology. World Health Organization and Response Evaluation Criteria in Solid Tumors (RECIST) are anatomic response criteria developed mainly for cytotoxic chemotherapy. These criteria may not be optimal for biologic agents, some disease sites, and some regional therapies. Some alternatives of RECIST were developed, but RECIST v1.1 is validated in prospective studies, is widely accepted by regulatory agencies and has recently shown good performance for targeted cancer agents. The newest alternatives of RECIST are immune-specific response criteria for checkpoint inhibitors. Metabolic response assessments using positron emission tomography (PET) or PET/computed tomography may reflect the viability of cancer cells or functional changes that occur after anticancer treatments.